Integer’s (ITGR) Overweight Rating Reaffirmed at Piper Sandler

Piper Sandler reiterated their overweight rating on shares of Integer (NYSE:ITGR) in a research note published on Friday, Benzinga reports. They currently have a $140.00 price target on the medical equipment provider’s stock, up from their prior price target of $125.00.

Several other research firms have also recently commented on ITGR. Truist Financial reduced their target price on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research report on Friday. Bank of America upped their price objective on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Oppenheimer initiated coverage on shares of Integer in a research report on Tuesday, July 16th. They set an “outperform” rating and a $135.00 target price for the company. KeyCorp boosted their price target on shares of Integer from $139.00 to $144.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 15th. Finally, Citigroup raised their price objective on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Integer presently has a consensus rating of “Moderate Buy” and an average target price of $139.75.

Integer Stock Down 0.8 %

ITGR stock opened at $125.77 on Friday. Integer has a twelve month low of $73.40 and a twelve month high of $133.53. The firm has a market capitalization of $4.22 billion, a PE ratio of 41.10, a PEG ratio of 1.80 and a beta of 1.08. The company has a quick ratio of 1.96, a current ratio of 3.29 and a debt-to-equity ratio of 0.73. The stock has a 50-day simple moving average of $127.58 and a two-hundred day simple moving average of $120.99.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.07. The business had revenue of $431.42 million for the quarter, compared to analyst estimates of $440.59 million. Integer had a net margin of 6.31% and a return on equity of 11.48%. Integer’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.27 EPS. On average, equities analysts predict that Integer will post 5.3 EPS for the current fiscal year.

Insider Buying and Selling

In other Integer news, Director Jean M. Hobby sold 11,960 shares of the company’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $119.66, for a total transaction of $1,431,133.60. Following the completion of the sale, the director now directly owns 2,280 shares in the company, valued at $272,824.80. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 2.00% of the stock is owned by corporate insiders.

Institutional Trading of Integer

Hedge funds and other institutional investors have recently bought and sold shares of the stock. GSA Capital Partners LLP bought a new stake in Integer during the 1st quarter valued at $786,000. Blue Trust Inc. raised its stake in shares of Integer by 460.4% during the second quarter. Blue Trust Inc. now owns 5,643 shares of the medical equipment provider’s stock valued at $658,000 after acquiring an additional 4,636 shares during the last quarter. UniSuper Management Pty Ltd purchased a new stake in shares of Integer during the first quarter worth about $976,000. Moloney Securities Asset Management LLC bought a new stake in shares of Integer in the first quarter worth about $927,000. Finally, Earnest Partners LLC grew its stake in shares of Integer by 3.2% in the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock worth $139,911,000 after purchasing an additional 37,340 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.